Literature DB >> 25552705

Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study.

Patrice Chevallier1, Francoise Huguet2, Emmanuel Raffoux3, Anne Etienne4, Thibaut Leguay5, Francoise Isnard6, Nelly Robillard7, Thierry Guillaume8, Jacques Delaunay8, Aude Charbonnier4, Arnaud Pigneux5, Pierre Peterlin8, Marie C Bené7, William A Wegener9, David M Goldenberg9, Hervé Dombret3.   

Abstract

Entities:  

Keywords:  B-ALL; CD22; chemoimmunotherapy; epratuzumab; minimal residual disease; older patients; refractory; relapse

Mesh：

Substances：

Year:  2014        PMID： 25552705      PMCID： PMC4380733          DOI： 10.3324/haematol.2014.120220

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases.

Authors:  P Chevallier; N Robillard; G Houille; S Ayari; T Guillaume; J Delaunay; J-L Harousseau; H Avet-Loiseau; M Mohty; R Garand
Journal:  Leukemia       Date:  2008-10-30       Impact factor: 11.528

2.  High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.

Authors:  Susan O'Brien; Gary Schiller; John Lister; Lloyd Damon; Stuart Goldberg; Walter Aulitzky; Dina Ben-Yehuda; Wendy Stock; Steven Coutre; Dan Douer; Leonard T Heffner; Melissa Larson; Karen Seiter; Scott Smith; Sarit Assouline; Philip Kuriakose; Lori Maness; Arnon Nagler; Jacob Rowe; Markus Schaich; Ofer Shpilberg; Karen Yee; Guenter Schmieder; Jeffrey A Silverman; Deborah Thomas; Steven R Deitcher; Hagop Kantarjian
Journal:  J Clin Oncol       Date:  2012-11-19       Impact factor: 44.544

3.  Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2.

Authors:  Elizabeth A Raetz; Mitchell S Cairo; Michael J Borowitz; Xiaomin Lu; Meenakshi Devidas; Joel M Reid; David M Goldenberg; William A Wegener; Hui Zeng; James A Whitlock; Peter C Adamson; Stephen P Hunger; William L Carroll
Journal:  Pediatr Blood Cancer       Date:  2015-03-02       Impact factor: 3.167

4.  Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation.

Authors:  Nicola Gökbuget; Daniel Stanze; Joachim Beck; Helmut Diedrich; Heinz-August Horst; Andreas Hüttmann; Guido Kobbe; Karl-Anton Kreuzer; Lothar Leimer; Albrecht Reichle; Markus Schaich; Stefan Schwartz; Hubert Serve; Michael Starck; Matthias Stelljes; Reingard Stuhlmann; Andreas Viardot; Knut Wendelin; Mathias Freund; Dieter Hoelzer
Journal:  Blood       Date:  2012-04-04       Impact factor: 22.113

5.  Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.

Authors:  Elizabeth A Raetz; Mitchell S Cairo; Michael J Borowitz; Susan M Blaney; Mark D Krailo; Tarek A Leil; Joel M Reid; David M Goldenberg; William A Wegener; William L Carroll; Peter C Adamson
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

6.  Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.

Authors:  John P Leonard; Morton Coleman; Jamie C Ketas; Amy Chadburn; Richard Furman; Michael W Schuster; Eric J Feldman; Michelle Ashe; Stephen J Schuster; William A Wegener; Hans J Hansen; Heather Ziccardi; Michael Eschenberg; Urte Gayko; Scott Z Fields; Alessandra Cesano; David M Goldenberg
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

7.  SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia.

Authors:  Anjali S Advani; Shannon McDonough; Steven Coutre; Brent Wood; Jerald Radich; Martha Mims; Margaret O'Donnell; Stephanie Elkins; Michael Becker; Megan Othus; Frederick R Appelbaum
Journal:  Br J Haematol       Date:  2014-03-03       Impact factor: 6.998

8.  Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.

Authors:  Kheira Beldjord; Sylvie Chevret; Vahid Asnafi; Françoise Huguet; Marie-Laure Boulland; Thibaut Leguay; Xavier Thomas; Jean-Michel Cayuela; Nathalie Grardel; Yves Chalandon; Nicolas Boissel; Beat Schaefer; Eric Delabesse; Hélène Cavé; Patrice Chevallier; Agnès Buzyn; Thierry Fest; Oumedaly Reman; Jean-Paul Vernant; Véronique Lhéritier; Marie C Béné; Marina Lafage; Elizabeth Macintyre; Norbert Ifrah; Hervé Dombret
Journal:  Blood       Date:  2014-04-16       Impact factor: 22.113

9.  BCR-ABL1 molecular remission after 90Y-epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B-ALL: proof of principle.

Authors:  Patrice Chevallier; Caroline Bodet-Milin; Nelly Robillard; Thomas Eugene; Audrey Menard; Claire Le Houerou; Thierry Guillaume; Jacques Delaunay; Martine Escoffre-Barbe; William A Wegener; David M Goldenberg; Francoise Kraeber-Bodéré
Journal:  Eur J Haematol       Date:  2013-09-12       Impact factor: 2.997

10.  Acute lymphoblastic leukemia in the elderly: results of two different treatment approaches in 49 patients during a 25-year period.

Authors:  A Ferrari; L Annino; S Crescenzi; C Romani; F Mandelli
Journal:  Leukemia       Date:  1995-10       Impact factor: 11.528
View more
  8 in total

1.  Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia.

Authors:  Patrice Chevallier; Sylvain Chantepie; Francoise Huguet; Emmanuel Raffoux; Xavier Thomas; Thibaut Leguay; Tony Marchand; Francoise Isnard; Aude Charbonnier; Sébastien Maury; Maria-Pilar Gallego-Hernanz; Nelly Robillard; Thierry Guillaume; Pierre Peterlin; Alice Garnier; Fanny Rialland; Claire Le Houerou; David M Goldenberg; William A Wegener; Marie-C Béné; Hervé Dombret
Journal:  Haematologica       Date:  2017-02-02       Impact factor: 9.941

Review 2.  Future of Therapy in Acute Lymphoblastic Leukemia (ALL)--Potential Role of Immune-Based Therapies.

Authors:  Partow Kebriaei; Michelle Limei Poon
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

Review 3.  Blinatumomab for the treatment of acute lymphoblastic leukemia.

Authors:  Jason B Kaplan; Marina Grischenko; Francis J Giles
Journal:  Invest New Drugs       Date:  2015-09-17       Impact factor: 3.850

Review 4.  Recent advances and novel treatment paradigms in acute lymphocytic leukemia.

Authors:  Nikolaos Papadantonakis; Anjali S Advani
Journal:  Ther Adv Hematol       Date:  2016-06-29

Review 5.  Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults.

Authors:  Aharon Ronson; Ariella Tvito; Jacob M Rowe
Journal:  Curr Oncol Rep       Date:  2016-06       Impact factor: 5.075

Review 6.  Sialic Acid-Siglec Axis as Molecular Checkpoints Targeting of Immune System: Smart Players in Pathology and Conventional Therapy.

Authors:  Przemyslaw Wielgat; Karol Rogowski; Katarzyna Niemirowicz-Laskowska; Halina Car
Journal:  Int J Mol Sci       Date:  2020-06-19       Impact factor: 5.923

7.  A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy.

Authors:  Yu Zhang; Saisai Li; Ying Wang; Yang Lu; Yingxi Xu; Qing Rao; Huijun Wang; Haiyan Xing; Zheng Tian; Kejing Tang; Lulu Lv; Min Wang; Jianxiang Wang
Journal:  Exp Hematol Oncol       Date:  2022-03-22

8.  CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.

Authors:  Terry J Fry; Nirali N Shah; Rimas J Orentas; Maryalice Stetler-Stevenson; Constance M Yuan; Sneha Ramakrishna; Pamela Wolters; Staci Martin; Cindy Delbrook; Bonnie Yates; Haneen Shalabi; Thomas J Fountaine; Jack F Shern; Robbie G Majzner; David F Stroncek; Marianna Sabatino; Yang Feng; Dimiter S Dimitrov; Ling Zhang; Sang Nguyen; Haiying Qin; Boro Dropulic; Daniel W Lee; Crystal L Mackall
Journal:  Nat Med       Date:  2017-11-20       Impact factor: 53.440
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.